Upcoming drug targets for kidney protective effects in chronic kidney disease
This review examines several new drug targets for chronic kidney disease, including GLP1 receptor agonists, aldosterone synthase inhibitors, endothelin receptor antagonists, soluble guanylate cyclase activators, and anti-inflammatory drugs. These medications show potential for reducing kidney disease progression by addressing various pathways involved in kidney damage, including metabolic, hemodynamic, and inflammatory processes. Further research, including large-scale clinical trials, is needed to confirm their efficacy and safety in diverse CKD populations.